相关临床试验
39
13 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
12
30.8%
已完成
24
61.5%
尚未招募
1
2.6%
招募中
1
2.6%
终止
1
2.6%
暂无批准数据
- Scientists at Imperial College London and The University of Manchester used genome mining to discover a new family of polyene antifungal agents published in Nature. - The lead compound Nys34 demonstrated reduced fungal burden in a mouse model of invasive aspergillosis without substantive signs of toxicity. - Nys34 employs a different mode of action than amphotericin, potentially overcoming resistance in emerging fungal pathogens. - The enzyme-based production platform offers a scalable, cost-effective alternative to complex chemical synthesis, potentially expanding access in lower-income regions.
- Researchers at The University of Manchester have secured nearly £1 million in funding from UK Research and Innovation to develop miniature soft robots inspired by snail locomotion for precise bowel cancer drug delivery. - The bio-inspired robots are designed to anchor themselves within malignant tissue and release therapeutic payloads in a controlled manner, potentially improving drug concentration at tumor sites while reducing off-target toxicity. - The project combines biology, materials science, and robotics to address the challenge of navigating complex environments like the gastrointestinal tract with high accuracy for targeted anti-cancer therapies. - The robots will be constructed from peptide-based bionanomaterials that respond to external triggers such as magnetic fields, enabling non-invasive remote control by clinicians.
- Poolbeg Pharma's POLB 001 trial will be central to the RISE programme, a £3.4 million MRC-funded initiative led by The University of Manchester and The Christie NHS Foundation Trust to address cytokine release syndrome in cancer immunotherapy. - The p38-MAP-kinase inhibitor POLB 001 aims to prevent CRS, which affects 50-90% of patients receiving bispecific antibody and CAR-T cell therapies, potentially making these breakthrough treatments safer and more accessible. - Poolbeg serves as lead business partner alongside Johnson & Johnson, which will provide the bispecific antibody teclistamab for the Phase IIa TOPICAL trial, with results expected in summer 2026.
- An international research team has developed and validated the first individualized risk prediction model for early-stage classic Hodgkin's lymphoma, called the Early-stage Hodgkin International Prognostication Index (E-HIPI). - The model was developed using data from over 3,000 patients in four international phase III clinical trials and validated in more than 2,300 patients from real-world registry cohorts. - E-HIPI uses routine clinical measures like patient sex, tumor size, hemoglobin and albumin levels to predict two-year progression-free survival and outperformed existing classification systems. - The research team created interactive online risk calculators to support shared decision-making between clinicians and patients, with findings published in NEJM Evidence.
